Adicet Bio
ACET
58 hedge funds and large institutions have $156M invested in Adicet Bio in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 22 increasing their positions, 13 reducing their positions, and 12 closing their positions.
69% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 13
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.26% less ownership
Funds ownership: 4.17% → 3.91% (-0.26%)
11% less funds holding
Funds holding: 65 → 58 (-7)
28% less capital invested
Capital invested by funds: $218M → $156M (-$61.9M)
50% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 12
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$2.07M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$1.31M |
| 3 |
6CM
683 Capital Management
New York
|
+$542K |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$465K |
| 5 |
State Street
Boston,
Massachusetts
|
+$349K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$10.6M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$5.02M |
| 3 |
VA
VR Adviser
New York
|
-$1.89M |
| 4 |
Millennium Management
New York
|
-$563K |
| 5 |
Two Sigma Investments
New York
|
-$442K |
ACET Hedge Fund Activity: Q3 2021 in Review
58 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Adicet Bio (ACET) for Q3 2021, worth a combined $156M — down 28% from $218M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ACET and 6 opened new positions — a net loss of 6 holders — while 13 trimmed existing stakes and 22 added.
The largest buyer was Ikarian Capital, adding an estimated $2.07M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $10.6M sold.
- 58 institutional investors held Adicet Bio (ACET) as of Q3 2021, down from 65 in Q2 2021.
- Funds reported $156M of Adicet Bio stock for Q3 2021, down 28% quarter-over-quarter.
- 6 funds opened new Adicet Bio positions in Q3 2021 and 12 closed out, a net change of -6 holders.
- The largest Adicet Bio buyer in Q3 2021 was Ikarian Capital, an estimated $2.07M added.
- The largest Adicet Bio seller in Q3 2021 was Consonance Capital Management, an estimated $10.6M sold.
Based on aggregated 13F filings for Q3 2021.